Business
Late-breaker abstract for SRA737 accepted for AACR
Late-breaker abstract for SRA737 accepted for AACR.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 7737H Sareum Holdings PLC 15 March 2018 \n\n (AIM: SAR) 15 March 2018\n \nSAREUM HOLDINGS PLC\n(\"Sareum\" or \"the Company\")\nSareum notes Sierra Oncology announcement that a late-breaking abstract reporting SRA737 preclinical activity in CCNE1-driven and PARP inhibitor-resistant cancers has been accepted for AACR 2018 Annual Meeting \n \nSareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, announced that late-breaking preclinical results for SRA737 have been accepted for presentation in a poster at the American Association of Cancer Research (AACR) Annual Meeting 2018 being held in Chicago, USA from 14-18 April. These data demonstrate that SRA737 has anti-tumour activity as a monotherapy in both CCNE1-driven cancer models and in cancer models resistant to poly ADP-ribose (PARP) inhibitor therapy, thereby warranting further investigation in human clinical studies. \nSierra Oncology recently announced that its ongoing Phase 1/2 monotherapy trial for SRA737 was being expanded to include an additional genetically-defined cohort, targeting enrolment of 20 patients with CCNE1-driven ovarian cancer. Approximately 20% of high grade serous ovarian cancers have an amplification of the CCNE1 gene, which is also prevalent across several other tumour types under evaluation in Sierra Oncology's ongoing clinical development programme, including non-small cell lung, colore...